A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs

Trial Profile

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PALACE-4
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 16 Jun 2018 Results of long term 5 year efficacy and safety presented at the 19th Annual Congress of the European League Against Rheumatism
    • 04 Apr 2018 Results (n=527) assessing efficacy and tolerability of apremilast [CC 10004] (40 mg/day versus 60 mg/day) in patients with psoriatic arthritis who have not been previously treated with disease modifying anti-rheumatic drugs, were published in the Rheumatology.
    • 08 Nov 2017 Long term efficacy and safety results of Apremilast montherapy, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top